Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of tiragolumab and/or atezolizumab after definitive chemoradiotherapy for unresectable esophageal squamous cell carcinoma
MOH_2021-01-31_009225Phase 3Active, not recruiting
- Sponsor
- Roche Pharmaceuticals Israel
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Tiragolumab + atezolizumab, Atezolizumab + tiragolumab placebo and Double placebo (3 arms). Started Jan 2021; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on MOH_2021-01-31_009225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-31_009225.